Status:
COMPLETED
Chronic Hepatitis C and Insulin Resistance
Lead Sponsor:
Garvan Institute of Medical Research
Conditions:
Hepatitis C
Insulin Resistance
Eligibility:
MALE
25-55 years
Brief Summary
Chronic hepatitis C (CHC) is among the commonest chronic infectious disease in Australia with \>200,000 exposed persons. Amongst non-infectious chronic conditions- Type 2 diabetes, obesity and heart d...
Eligibility Criteria
Inclusion
- Caucasian male
- Age: 25-55 years
- Chronic Hepatitis C (PCR positive) and fibrosis ≤ F2 (if liver biopsy done)
- Genotypes 1 or 3
- Due to commence antiviral therapy
- BMI \< 30
Exclusion
- Cirrhosis or F3 fibrosis on liver biopsy (if done)
- \> 20 g ETOH per day
- Type 2 Diabetes (need an OGTT if fasting BGL\> 5.7)
- Concurrent HIV
- Other cause of liver disease
Key Trial Info
Start Date :
May 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00707603
Start Date
May 1 2006
End Date
December 1 2008
Last Update
July 14 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Garvan Institute Of Medical Research
Sydney, New South Wales, Australia, 2010
2
Storr Liver Unit
Sydney, New South Wales, Australia, 2145